Kostina Z I, Brazhenko N A, Nasorina R N
Probl Tuberk. 1995(3):34-7.
Long-term (3-25 years) responses to treatment are available for 1820 patients with respiratory sarcoidosis. 65.7% of them were females and 34.3% males primarily at the age of 21-50 (92.7%). Sarcoidosis of the intrathoracic lymph nodes (ITLN), sarcoidosis of the lungs and ITLN, diffuse forms of pulmonary sarcoidosis, generalized sarcoidosis were diagnosed in 64, 28.2, 4.6, 2.6% of patients, respectively. All the patients received combined pathogenetic treatment (hormones, antioxidants, antihypoxants, immunomodulators, angio- and hepatoprotectors) which proved highly long-acting in stage I-II (a complete response rate 84.3% and 82.7%, respectively, residual changes remained in 1/5 of the patients). Long-term recurrences occurred in 3.5% of patients who had marked residual changes in the lungs. The disease took a chronic course in 8.7%, progression was recorded in 9.3, lethal outcome in 0.7% of the cases.
1820例呼吸性结节病患者有长期（3 - 25年）的治疗反应数据。其中65.7%为女性，34.3%为男性，主要年龄在21 - 50岁（92.7%）。胸内淋巴结结节病（ITLN）、肺部及ITLN结节病、弥漫性肺结节病、全身性结节病的诊断率分别为64%、28.2%、4.6%、2.6%。所有患者均接受了综合病因治疗（激素、抗氧化剂、抗缺氧剂、免疫调节剂、血管和肝脏保护剂），在I - II期显示出高效长效（完全缓解率分别为84.3%和82.7%，1/5的患者仍有残留改变）。肺部有明显残留改变的患者中，3.5%出现长期复发。8.7%的病例病情呈慢性病程，9.3%有病情进展记录，0.7%的病例出现致命结局。
